Amrad, Ludwig beef up agreement
Wednesday, 03 November, 2004
Amrad (ASX:AML) and the Ludwig Institute for Cancer Research have strengthened their collaboration for the development of vascular endothelial growth factor B (VEGF-B), which has potential applications in cancer and cardiovascular disease.
Under the agreement, the partners will coordinate research, development and commercialisation activities to appropriately leverage the combined expertise of the two groups. Intellectual property generated since the original agreement was reached will also be brought together.
Amrad is developing antibodies against VEGF-B for evaluation as potential cancer treatments, in addition to evaluating VEGF-B in coronary disease models. Ludwig researchers in Sweden and Finland will work closely with Amrad to move therapies based on VEGF-B into the clinic as soon as possible.
Lipid science receives new Australia-led online hub
The Lipid Network launched this month to build links between researchers, clinicians and industry...
Proposed Australian trial eyes up blood testing for Alzheimer's
Utilising networks of GPs across three states, a large-scale study intends on combining digital...
Applications open for $300K pandemic therapeutics fellowships
Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...
